Potential and limitations of bone anabolic therapy with parathyroid hormone

European Cells and Materials

Volumn 5, Issue SUPPL. 2, 2003, Pages 34-36

  Gasser, J A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861750751     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. JM Hock and I Gera (1992) J Bone Miner Res 7:65-72.
2. H Dobnig and RT Turner (1997) Endocrinology 138:4607-12.
3. T Ishizuya, S Yokose, M Hori, et al (1997) J Clin Invest 99:2961-70.
4. H Dobnig and RT Turner (1995) Endocrinology 136:3632-8.
5. CP Jerome (1994) J Bone Miner Res 9:933-42.
6. CP Jerome, CS Johnson and CJ Lees (1995) Bone 17:(Suppl. October) 415S-20S.
7. H Qi, M Li and TJ Wronski (1995) J Bone Miner Res 10:948-55.
8. JA Gasser (1997) J Jpn Soc Bone Morphom 7:107-114.
9. JA Gasser and CP Jerome (1992) Triangle 31:111-21.
10. V Shen, R Birchman, and R Xu et al (1995) J Clin Invest 96:2331-8.
11. CP Jerome, DB Burr, T Van Bibber et al (2001) Bone 28:150-9.
12. M Kneissel, A Boyde and JA Gasser (2001) Bone 28:237-50.
13. R Neer et al (2001) NEJM 344:1434-41.
14. NE Lane, S Sanchez, GW Modin et al., (2000) J Bone Miner Res 15:944-51.
15. R Lindsay, J Nieves, C Formica et al (1997) Lancet 350:23, 550-5.
16. JA Gasser, M Kneissel, JS Thomsen et al (2000) J Musculoskel Neuronal Interact 1:53-56.